Sarepta Entered into a Research Collaboration and Option Agreement with GenEdit to Develop Gene Editing Therapies for Neuromuscular Diseases
Shots:
- GenEdit to receive ~$57M up front and is also eligible to receive future development, regulatory and commercial milestones along with royalties. Sarepta gets exclusive option rights to license polymer nanoparticles that were developed by GenEdit for 4 neuromuscular indications
- The collaboration will combine Sarepta’s gene-editing technologies and GenEdit’s non-viral delivery platform to develop new genetic therapies for patients with neuromuscular diseases
- Additionally, in vivo results showed the potential of GenEdit’s polymer nanoparticles to deliver therapeutic cargo at muscle tissue after systemic administration to target & non-viral systemic delivery of genetic medicines
Ref: Globe Newswire | Image: Fierce Biotech
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com